COGENT BIOSCIENCES ($COGT) is expected to release its quarterly earnings data on Monday, November 17th before market open, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.54 per share.
You can see Quiver Quantitative's $COGT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COGENT BIOSCIENCES Insider Trading Activity
COGENT BIOSCIENCES insiders have traded $COGT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $COGT stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 2,777,777 shares for an estimated $24,999,993
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
COGENT BIOSCIENCES Hedge Fund Activity
We have seen 113 institutional investors add shares of COGENT BIOSCIENCES stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 5,329,795 shares (+31.2%) to their portfolio in Q3 2025, for an estimated $76,535,856
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 3,236,590 shares (-55.1%) from their portfolio in Q2 2025, for an estimated $23,238,716
- JANUS HENDERSON GROUP PLC added 2,843,980 shares (+9782.2%) to their portfolio in Q2 2025, for an estimated $20,419,776
- REDMILE GROUP, LLC removed 1,767,986 shares (-55.0%) from their portfolio in Q2 2025, for an estimated $12,694,139
- BLACKROCK, INC. added 1,742,954 shares (+20.2%) to their portfolio in Q3 2025, for an estimated $25,028,819
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,734,601 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $24,908,870
- UBS GROUP AG removed 1,664,999 shares (-47.3%) from their portfolio in Q3 2025, for an estimated $23,909,385
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
COGENT BIOSCIENCES Analyst Ratings
Wall Street analysts have issued reports on $COGT in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2025
- Leerink Partners issued a "Outperform" rating on 11/10/2025
- JP Morgan issued a "Overweight" rating on 10/21/2025
- Raymond James issued a "Strong Buy" rating on 09/03/2025
- Citigroup issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for COGENT BIOSCIENCES, check out Quiver Quantitative's $COGT forecast page.
COGENT BIOSCIENCES Price Targets
Multiple analysts have issued price targets for $COGT recently. We have seen 11 analysts offer price targets for $COGT in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $50.0 on 11/13/2025
- Colleen Kusy from Baird set a target price of $34.0 on 11/11/2025
- Andrew Berens from Leerink Partners set a target price of $50.0 on 11/10/2025
- Anupam Rama from JP Morgan set a target price of $44.0 on 10/21/2025
- Laura Prendergast from Stifel set a target price of $16.0 on 10/16/2025
- Chris Raymond from Raymond James set a target price of $30.0 on 09/03/2025
- Charles Zhou from Guggenheim set a target price of $20.0 on 08/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
